I am Dileep Lobo from UK. Before we began the debate, I posed a question to the audience: "How many of you would consider giving your patient a drug that wouldn't even pass a Phase 1 clinical trial?" That question set the tone for the discussion. Today, I gave two lectures. The first was a debate on 0.9% saline versus balanced crystalloids, in which I argued in favor of balanced crystalloids as the superior option. I'm pleased to share that by the end of the session, we won the audience vote—a great sign that the evidence and arguments resonated. I believe the IFAD Congress has truly evolved over the years. I've been attending for the past three editions, and with each one, the program gets even stronger. We're treated to state-of-the-art lectures by world-renowned experts, and the interactive discussions allow for healthy debate around current evidence, giving the audience the opportunity to form their own informed opinions. What also stands out is the congress's commitment to forward-looking insights—highlighting not only where we are today but also where the field of fluid therapy and critical care is heading. As with previous years, I've thoroughly enjoyed this conference, and I look forward to seeing how it continues to grow.

Ver todos los episodios